Mitapivat (Aqvesme)
Small molecule
Evidence outlook
Approved: Transfusion-Dependent Beta Thalassemia
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
ENERGIZE-T NCT04770779 · Transfusion-Dependent Beta Thalassemia The study was randomized, quadruple-blind, and placebo-controlled, with 258 participants, and its clinical primary endpoint was met in favor of mitapivat. However, no primary-endpoint power calculation is reported in the provided record, so the evidence is graded moderate rather than strong. Registry: NCT04770779 | 3 | Double-blind Period: Percentage of Participants Who Achieved Transfusion Reduction Response (TRR) (Double-blind Period: Baseline through Week 48) 2024-04-11 | Transfusion reduction response in the double-blind period (baseline through Week 48), mitapivat vs placebo: 30.4% vs 12.6%, common risk difference 17.6 percentage points (95% CI 8.0 to 27.2), p=0.0003 (CT.gov posted results). | Partial signal | link ↗ |
View 1 more trial
ENERGIZE NCT04770753 · Non-Transfusion-dependent Alpha-Thalassemia The trial randomized 194 participants to quadruple-blinded mitapivat or matching placebo and used a clinical hemoglobin-response endpoint, which was met in favor of mitapivat (42.3% vs 1.6%; p<0.0001). It is graded moderate because the registry does not report the power calculation needed to confirm that the enrolled sample was adequately powered. Registry: NCT04770753 | 3 | Double-Blind Period: Percentage of Participants Who Achieved Hemoglobin (Hb) Response From Week 12 Through Week 24 Compared With Baseline (Double-Blind Period: Baseline up to Week 12 through Week 24) 2023-11-13 | Hemoglobin response from Week 12 through Week 24 in the double-blind period, mitapivat vs placebo: 42.3% vs 1.6%, difference 40.9 percentage points (95% CI 32.0 to 49.8), p<0.0001 (CT.gov posted results). | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (2)
What this study did
What this study did
Competitive landscape
Other Pyruvate kinase drugs
2 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Transfusion-Dependent Beta Thalassemia: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Mitapivat (Aqvesme): this drug | Approved | Small molecule | Pyruvate kinase | Partial signal | NCT04770779: Transfusion reduction response in the double-blind period (baseline through Week 48), mitapivat vs placebo: 30.4% vs 12.6%, common risk difference 17.6 percentage points (95% CI 8.0 to 27.2), p=0.0003 (CT.gov posted results). NCT04770753: Hemoglobin response from Week 12 through Week 24 in the double-blind period, mitapivat vs placebo: 42.3% vs 1.6%, difference 40.9 percentage points (95% CI 32.0 to 49.8), p<0.0001 (CT.gov posted results). | |
| Exagamglogene Autotemcel (Casgevy) | Approved | Gene therapy / editing | BCL11A erythroid enhancer (gene editing) | not yet graded | No reviewed efficacy summary in this indication | |
| Etavopivat | Phase 3(overall) | — | Pyruvate kinase | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Mitapivat (Pyrukynd) | Phase 3 | Small molecule | Pyruvate kinase | not yet graded | No reviewed efficacy summary in this indication | |
| Renizgamglogene Autogedtemcel | Discontinued | Gene or cell therapy (subtype unspecified) | HBG1/HBG2 promoters | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
No upcoming readouts on record for this asset.